Loading…
Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer
Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healt...
Saved in:
Published in: | International journal of molecular sciences 2023-10, Vol.24 (20), p.15232 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53 |
container_end_page | |
container_issue | 20 |
container_start_page | 15232 |
container_title | International journal of molecular sciences |
container_volume | 24 |
creator | Biniari, Georgia Markatos, Christos Nteli, Agathi Tzoupis, Haralambos Simal, Carmen Vlamis-Gardikas, Alexios Karageorgos, Vlasios Pirmettis, Ioannis Petrou, Panagiota Venihaki, Maria Liapakis, George Tselios, Theodore |
description | Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies. |
doi_str_mv | 10.3390/ijms242015232 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_163ffd16e2914e6abafa99093e73c1f4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771910558</galeid><doaj_id>oai_doaj_org_article_163ffd16e2914e6abafa99093e73c1f4</doaj_id><sourcerecordid>A771910558</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53</originalsourceid><addsrcrecordid>eNptkl1v0zAUhiMEYmNwyb0lboZEhh3ny1eo66CtNAmphWvrxB-Zq8Tu7KSof5NfhLNWQBHKRY7s532SY58keUvwDaUMfzTbPmR5hkmR0exZcknyLEsxLqvnf9UXyasQthhHpGAvkwta1SxnJLtMfq5hMM5Ch-5UMK39gDYHOzzEOiCwEt0aK41t0UxrY81wQJthlEYF5DSaRdDD42issyrmvdlH2T5uzp3dji0MSqLBoUX0Szd4tzM2XatOQZiUS-f7KXi9sOvl-2iDzrVjTA_uB3gZ0CaiYhKiVd-P1oVxt_MqhPi_0-dP-fRO7ZSVyg5oDlYo_zp5oaEL6s3pfZV8__L523yZ3n9drOaz-1TkdTakDZZaMwKl1KTJoGCyYlUsS12UWdnopiigoZTkAkBKWueVUjIvRVWCFFgX9CpZHb3SwZbvvOnBH7gDw58WnG85-MGITnFSUq0lKVXGSK5KaEADY5hRVVFBdB5dn46u3dj0SorYjYfuTHq-Y80Db92eE1ziipQ4Gq5PBu8e4ykOvDdBqK4Dq9wYeFbXtKjznLGIvvsH3brRx-N_ouKEFKSq_1AtxA6M1fEGQUxSPqsqwgguiom6-Q8VH6l6I-L1aBPXzwLpMSC8C8Er_btJgvk00fxsoukv1UjtKQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882595178</pqid></control><display><type>article</type><title>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Biniari, Georgia ; Markatos, Christos ; Nteli, Agathi ; Tzoupis, Haralambos ; Simal, Carmen ; Vlamis-Gardikas, Alexios ; Karageorgos, Vlasios ; Pirmettis, Ioannis ; Petrou, Panagiota ; Venihaki, Maria ; Liapakis, George ; Tselios, Theodore</creator><creatorcontrib>Biniari, Georgia ; Markatos, Christos ; Nteli, Agathi ; Tzoupis, Haralambos ; Simal, Carmen ; Vlamis-Gardikas, Alexios ; Karageorgos, Vlasios ; Pirmettis, Ioannis ; Petrou, Panagiota ; Venihaki, Maria ; Liapakis, George ; Tselios, Theodore</creatorcontrib><description>Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms242015232</identifier><identifier>PMID: 37894912</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Cancer ; Cancer therapies ; Chemical bonds ; Cytotoxicity ; Drug delivery systems ; Drugs ; Gonadotropin ; gonadotropin-releasing hormone (GnRH) ; hormone-dependent cancer ; Human reproduction ; Hypothalamus ; Immunotherapy ; Medical research ; Medicine, Experimental ; mitoxantrone ; Ovaries ; Peptides ; Pituitary hormones ; Prostate ; targeted cancer therapy ; Thioredoxin ; thioredoxin system ; Toxicity ; Vehicles</subject><ispartof>International journal of molecular sciences, 2023-10, Vol.24 (20), p.15232</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53</cites><orcidid>0000-0003-4933-7723 ; 0000-0002-3789-8032 ; 0009-0000-5789-8884 ; 0000-0002-1534-2762 ; 0000-0001-5068-6459 ; 0009-0001-9386-7169 ; 0000-0003-0022-3725 ; 0000-0002-7096-4281 ; 0000-0002-1310-0591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2882595178/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2882595178?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Biniari, Georgia</creatorcontrib><creatorcontrib>Markatos, Christos</creatorcontrib><creatorcontrib>Nteli, Agathi</creatorcontrib><creatorcontrib>Tzoupis, Haralambos</creatorcontrib><creatorcontrib>Simal, Carmen</creatorcontrib><creatorcontrib>Vlamis-Gardikas, Alexios</creatorcontrib><creatorcontrib>Karageorgos, Vlasios</creatorcontrib><creatorcontrib>Pirmettis, Ioannis</creatorcontrib><creatorcontrib>Petrou, Panagiota</creatorcontrib><creatorcontrib>Venihaki, Maria</creatorcontrib><creatorcontrib>Liapakis, George</creatorcontrib><creatorcontrib>Tselios, Theodore</creatorcontrib><title>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</title><title>International journal of molecular sciences</title><description>Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemical bonds</subject><subject>Cytotoxicity</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Gonadotropin</subject><subject>gonadotropin-releasing hormone (GnRH)</subject><subject>hormone-dependent cancer</subject><subject>Human reproduction</subject><subject>Hypothalamus</subject><subject>Immunotherapy</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>mitoxantrone</subject><subject>Ovaries</subject><subject>Peptides</subject><subject>Pituitary hormones</subject><subject>Prostate</subject><subject>targeted cancer therapy</subject><subject>Thioredoxin</subject><subject>thioredoxin system</subject><subject>Toxicity</subject><subject>Vehicles</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1v0zAUhiMEYmNwyb0lboZEhh3ny1eo66CtNAmphWvrxB-Zq8Tu7KSof5NfhLNWQBHKRY7s532SY58keUvwDaUMfzTbPmR5hkmR0exZcknyLEsxLqvnf9UXyasQthhHpGAvkwta1SxnJLtMfq5hMM5Ch-5UMK39gDYHOzzEOiCwEt0aK41t0UxrY81wQJthlEYF5DSaRdDD42issyrmvdlH2T5uzp3dji0MSqLBoUX0Szd4tzM2XatOQZiUS-f7KXi9sOvl-2iDzrVjTA_uB3gZ0CaiYhKiVd-P1oVxt_MqhPi_0-dP-fRO7ZSVyg5oDlYo_zp5oaEL6s3pfZV8__L523yZ3n9drOaz-1TkdTakDZZaMwKl1KTJoGCyYlUsS12UWdnopiigoZTkAkBKWueVUjIvRVWCFFgX9CpZHb3SwZbvvOnBH7gDw58WnG85-MGITnFSUq0lKVXGSK5KaEADY5hRVVFBdB5dn46u3dj0SorYjYfuTHq-Y80Db92eE1ziipQ4Gq5PBu8e4ykOvDdBqK4Dq9wYeFbXtKjznLGIvvsH3brRx-N_ouKEFKSq_1AtxA6M1fEGQUxSPqsqwgguiom6-Q8VH6l6I-L1aBPXzwLpMSC8C8Er_btJgvk00fxsoukv1UjtKQ</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Biniari, Georgia</creator><creator>Markatos, Christos</creator><creator>Nteli, Agathi</creator><creator>Tzoupis, Haralambos</creator><creator>Simal, Carmen</creator><creator>Vlamis-Gardikas, Alexios</creator><creator>Karageorgos, Vlasios</creator><creator>Pirmettis, Ioannis</creator><creator>Petrou, Panagiota</creator><creator>Venihaki, Maria</creator><creator>Liapakis, George</creator><creator>Tselios, Theodore</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4933-7723</orcidid><orcidid>https://orcid.org/0000-0002-3789-8032</orcidid><orcidid>https://orcid.org/0009-0000-5789-8884</orcidid><orcidid>https://orcid.org/0000-0002-1534-2762</orcidid><orcidid>https://orcid.org/0000-0001-5068-6459</orcidid><orcidid>https://orcid.org/0009-0001-9386-7169</orcidid><orcidid>https://orcid.org/0000-0003-0022-3725</orcidid><orcidid>https://orcid.org/0000-0002-7096-4281</orcidid><orcidid>https://orcid.org/0000-0002-1310-0591</orcidid></search><sort><creationdate>20231001</creationdate><title>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</title><author>Biniari, Georgia ; Markatos, Christos ; Nteli, Agathi ; Tzoupis, Haralambos ; Simal, Carmen ; Vlamis-Gardikas, Alexios ; Karageorgos, Vlasios ; Pirmettis, Ioannis ; Petrou, Panagiota ; Venihaki, Maria ; Liapakis, George ; Tselios, Theodore</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemical bonds</topic><topic>Cytotoxicity</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Gonadotropin</topic><topic>gonadotropin-releasing hormone (GnRH)</topic><topic>hormone-dependent cancer</topic><topic>Human reproduction</topic><topic>Hypothalamus</topic><topic>Immunotherapy</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>mitoxantrone</topic><topic>Ovaries</topic><topic>Peptides</topic><topic>Pituitary hormones</topic><topic>Prostate</topic><topic>targeted cancer therapy</topic><topic>Thioredoxin</topic><topic>thioredoxin system</topic><topic>Toxicity</topic><topic>Vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biniari, Georgia</creatorcontrib><creatorcontrib>Markatos, Christos</creatorcontrib><creatorcontrib>Nteli, Agathi</creatorcontrib><creatorcontrib>Tzoupis, Haralambos</creatorcontrib><creatorcontrib>Simal, Carmen</creatorcontrib><creatorcontrib>Vlamis-Gardikas, Alexios</creatorcontrib><creatorcontrib>Karageorgos, Vlasios</creatorcontrib><creatorcontrib>Pirmettis, Ioannis</creatorcontrib><creatorcontrib>Petrou, Panagiota</creatorcontrib><creatorcontrib>Venihaki, Maria</creatorcontrib><creatorcontrib>Liapakis, George</creatorcontrib><creatorcontrib>Tselios, Theodore</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Health and Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biniari, Georgia</au><au>Markatos, Christos</au><au>Nteli, Agathi</au><au>Tzoupis, Haralambos</au><au>Simal, Carmen</au><au>Vlamis-Gardikas, Alexios</au><au>Karageorgos, Vlasios</au><au>Pirmettis, Ioannis</au><au>Petrou, Panagiota</au><au>Venihaki, Maria</au><au>Liapakis, George</au><au>Tselios, Theodore</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer</atitle><jtitle>International journal of molecular sciences</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>24</volume><issue>20</issue><spage>15232</spage><pages>15232-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Gonadotropin-releasing hormone (GnRH) is pivotal in regulating human reproduction and fertility through its specific receptors. Among these, gonadotropin-releasing hormone receptor type I (GnRHR I), which is a member of the G-protein-coupled receptor family, is expressed on the surface of both healthy and malignant cells. Its presence in cancer cells has positioned this receptor as a primary target for the development of novel anti-cancer agents. Moreover, the extensive regulatory functions of GnRH have underscored decapeptide as a prominent vehicle for targeted drug delivery, which is accomplished through the design of appropriate conjugates. On this basis, a rationally designed series of anthraquinone/mitoxantrone–GnRH conjugates (con1–con8) has been synthesized herein. Their in vitro binding affinities range from 0.06 to 3.42 nM, with six of them (con2–con7) demonstrating higher affinities for GnRH than the established drug leuprolide (0.64 nM). Among the mitoxantrone based GnRH conjugates, con3 and con7 show the highest affinities at 0.07 and 0.06 nM, respectively, while the disulfide bond present in the conjugates is found to be readily reduced by the thioredoxin (Trx) system. These findings are promising for further pharmacological evaluation of the synthesized conjugates with the prospect of performing future clinical studies.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37894912</pmid><doi>10.3390/ijms242015232</doi><orcidid>https://orcid.org/0000-0003-4933-7723</orcidid><orcidid>https://orcid.org/0000-0002-3789-8032</orcidid><orcidid>https://orcid.org/0009-0000-5789-8884</orcidid><orcidid>https://orcid.org/0000-0002-1534-2762</orcidid><orcidid>https://orcid.org/0000-0001-5068-6459</orcidid><orcidid>https://orcid.org/0009-0001-9386-7169</orcidid><orcidid>https://orcid.org/0000-0003-0022-3725</orcidid><orcidid>https://orcid.org/0000-0002-7096-4281</orcidid><orcidid>https://orcid.org/0000-0002-1310-0591</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2023-10, Vol.24 (20), p.15232 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_163ffd16e2914e6abafa99093e73c1f4 |
source | Publicly Available Content (ProQuest); PubMed Central |
subjects | Cancer Cancer therapies Chemical bonds Cytotoxicity Drug delivery systems Drugs Gonadotropin gonadotropin-releasing hormone (GnRH) hormone-dependent cancer Human reproduction Hypothalamus Immunotherapy Medical research Medicine, Experimental mitoxantrone Ovaries Peptides Pituitary hormones Prostate targeted cancer therapy Thioredoxin thioredoxin system Toxicity Vehicles |
title | Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A34%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rational%20Design,%20Synthesis%20and%20Binding%20Affinity%20Studies%20of%20Anthraquinone%20Derivatives%20Conjugated%20to%20Gonadotropin-Releasing%20Hormone%20(GnRH)%20Analogues%20towards%20Selective%20Immunosuppression%20of%20Hormone-Dependent%20Cancer&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Biniari,%20Georgia&rft.date=2023-10-01&rft.volume=24&rft.issue=20&rft.spage=15232&rft.pages=15232-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms242015232&rft_dat=%3Cgale_doaj_%3EA771910558%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c482t-b0dff91a6df1b2a59d797f1b6f5626bfb55ab3314caadd3847eed46c76adc0f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2882595178&rft_id=info:pmid/37894912&rft_galeid=A771910558&rfr_iscdi=true |